Analysts expect Kala Pharmaceuticals Inc (NASDAQ:KALA) to report ($0.41) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Kala Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.28) and the lowest estimate coming in at ($0.56). Kala Pharmaceuticals posted earnings of ($0.70) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 41.4%. The company is scheduled to issue its next quarterly earnings results on Tuesday, August 4th.
On average, analysts expect that Kala Pharmaceuticals will report full-year earnings of ($1.72) per share for the current financial year, with EPS estimates ranging from ($2.42) to ($1.10). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.27) per share, with EPS estimates ranging from ($2.27) to ($0.84). Zacks’ earnings per share calculations are an average based on a survey of research firms that cover Kala Pharmaceuticals.
Kala Pharmaceuticals (NASDAQ:KALA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.54) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.51) by ($0.03). The company had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $2.49 million. Kala Pharmaceuticals had a negative return on equity of 132.08% and a negative net margin of 1,578.64%.
Shares of NASDAQ:KALA traded up $0.06 during midday trading on Friday, reaching $12.31. The company had a trading volume of 894,453 shares, compared to its average volume of 1,259,511. The company’s 50 day moving average price is $10.85 and its 200 day moving average price is $6.92. The company has a current ratio of 12.17, a quick ratio of 11.87 and a debt-to-equity ratio of 0.50. The stock has a market cap of $663.57 million, a P/E ratio of -4.83 and a beta of 0.26. Kala Pharmaceuticals has a 52-week low of $3.24 and a 52-week high of $13.55.
In related news, COO Todd Bazemore purchased 10,000 shares of the firm’s stock in a transaction dated Monday, March 16th. The shares were purchased at an average cost of $5.75 per share, for a total transaction of $57,500.00. Following the completion of the transaction, the chief operating officer now directly owns 10,000 shares in the company, valued at approximately $57,500. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Rajeev M. Shah purchased 6,337,135 shares of the firm’s stock in a transaction dated Friday, March 13th. The shares were bought at an average price of $7.89 per share, for a total transaction of $49,999,995.15. The disclosure for this purchase can be found here. Corporate insiders own 30.77% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in KALA. Citigroup Inc. increased its position in shares of Kala Pharmaceuticals by 217.5% during the fourth quarter. Citigroup Inc. now owns 7,379 shares of the company’s stock valued at $27,000 after buying an additional 5,055 shares during the period. Bank of Montreal Can increased its position in shares of Kala Pharmaceuticals by 334.2% in the fourth quarter. Bank of Montreal Can now owns 8,928 shares of the company’s stock worth $34,000 after purchasing an additional 6,872 shares during the last quarter. Nisa Investment Advisors LLC bought a new position in shares of Kala Pharmaceuticals in the first quarter worth approximately $44,000. Tower Research Capital LLC TRC increased its position in shares of Kala Pharmaceuticals by 196.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 12,131 shares of the company’s stock worth $45,000 after purchasing an additional 8,033 shares during the last quarter. Finally, Victory Capital Management Inc. increased its position in shares of Kala Pharmaceuticals by 82.2% in the first quarter. Victory Capital Management Inc. now owns 7,359 shares of the company’s stock worth $65,000 after purchasing an additional 3,320 shares during the last quarter. Hedge funds and other institutional investors own 73.60% of the company’s stock.
About Kala Pharmaceuticals
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
Featured Story: Day Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.